Bcr-Abl fusion gene drives the onset and development of CML, whereas the oncoprotein BCR-ABL with increased tyrosine kinase activity serves as a target for TKI treatment [33, 34]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.